Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate.

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML Asterias Biotherapeutics, Inc. , a biotechnology company centered on the emerging field of regenerative medication, today announced positive, new, long-term follow-up data from a Stage 2 scientific trial of AST-VAC1 in patients with intermediate and risky severe myelogenous leukemia . AST-VAC1 is the Company's autologous telomerase-based dendritic cell cancers vaccine. AML may be the most common form of severe leukemia in adults with 12,000 new situations diagnosed annually, and continues to be an unmet scientific need, especially in patients older than 60 who encounter poor outcomes and have limited therapies available to them. The long-term follow-up showed that a lot more than 50 percent of patients who received AST-VAC1 acquired prolonged relapse-free survival, actually patients with high-risk AML including those over 60 years old and individuals in second remission.

Astellas believes tacrolimus extended release capsules, provided the efficacy, safety profile and exclusive dosing schedule, provide a promising treatment choice for recipients potentially,’ said Roy First, MD, Astellas Global Therapeutic Region Head for Transplantation. ‘This submission is another example of Astellas’ longstanding commitment to the transplant community and the well-becoming of transplant recipients.’.. Astellas seeks FDA authorization for tacrolimus NDA for prophylaxis of organ rejection Astellas Pharma US, Inc. , a U.S. Subsidiary of Tokyo-centered Astellas Pharma Inc. , today announced it has submitted a New Drug Software to the U.S. Food and Medication Administration seeking acceptance for tacrolimus extended launch capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.